COVID-19 Vaccine Race: With Moderna EUA, US FDA Finally Gets Some Bragging Rights
US FDA’s global first for Moderna’s vaccine gets a small mention as agency looks to pharmacovigilance, follow-up studies for both coronavirus inoculations that have now been authorized. Moderna's 18 December EUA comes after an even faster review than for Pfizer/BioNTech's vaccine.
You may also be interested in...
However, recruitment for adult trials remains robust, OWS’ Slaoui says.
Moderna has received $2.8bn for advance purchase agreements for its COVID-19 vaccine, with much more to follow. Management outlined some initial financial updates for investors.
Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.